Mode
Text Size
Log in / Sign up

Probiotic regimens may reduce cough duration and illness length in children with respiratory infectionsProbiotics shorten cough and illness in children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that certain probiotic strains may reduce cough duration and illness length in children with respiratory infections.

The study evaluated the efficacy and safety of several probiotic regimens, including Bifidobacterium, Lactobacillus, and combination therapies, in children suffering from respiratory tract infections. The analysis focused on primary outcomes such as cough duration, total illness duration, fever duration, and the necessity of antibiotic use.

The findings indicated that Bifidobacterium was associated with a reduction in cough duration, while Lactobacillus was linked to shorter durations of both upper and lower respiratory tract illnesses. Furthermore, certain combination therapies showed potential in reducing fever and antibiotic requirements. However, the authors noted that evidence for the superiority of specific multi-strain combinations over single-strain regimens remains limited.

Several limitations were identified, including low-certainty evidence regarding the comparative advantages of Lactobacillus plus Bifidobacterium over other formulations for cough or antibiotic reduction. Clinicians should interpret these findings with caution; while some results suggest potential benefits for managing symptoms and reducing antibiotic exposure, more rigorously designed trials are needed to confirm the superiority of specific multi-strain combinations.

A new analysis of past studies suggests that certain probiotics may help otherwise healthy children recover faster from respiratory tract infections, such as colds and flu. The review combined data from multiple trials involving 1,158 children and looked at how different probiotic regimens affected symptoms like cough, fever, and how long the illness lasted.

The findings showed that Bifidobacterium probiotics shortened cough duration by about 1.12 days, while Lactobacillus shortened overall illness duration by about 1.31 days for upper respiratory infections and 1.36 days for lower respiratory infections. Lactobacillus also shortened antibiotic use by about 1.70 days in upper respiratory infections. A combination of Lactobacillus and Bifidobacterium shortened fever by about 2 days in upper respiratory infections and reduced fever and antibiotic use in recurrent respiratory infections by 7.10 and 10.50 days, respectively.

However, the evidence for the Lactobacillus and Bifidobacterium combination was low-certainty, meaning we can't be confident in those results. The analysis also found that one study reported similar rates of stomach-related side effects between probiotic and control groups, but other safety details were not reported.

This is a network meta-analysis, which is a type of study that combines results from multiple trials. While the findings are promising, they are not definitive. The authors note that more rigorous studies are needed to confirm the benefits of specific probiotic combinations. For now, parents should talk to their child's doctor before giving probiotics for an infection.

What this means for you:
Probiotics may shorten cold symptoms in kids, but evidence is mixed; ask a doctor first.

Common questions

Which probiotics helped shorten coughs in children?

The analysis found that Bifidobacterium shortened cough duration by about 1.12 days. A combination of Lactobacillus and Bifidobacterium also shortened cough in lower respiratory infections by 1.25 days, but that evidence was low-certainty.

Did probiotics reduce the need for antibiotics?

Yes, Lactobacillus shortened antibiotic use by about 1.70 days in upper respiratory infections. A Lactobacillus and Bifidobacterium combination also reduced antibiotic use by 10.50 days in recurrent respiratory infections, but that finding was low-certainty.

Are probiotics safe for children with respiratory infections?

One study in the analysis reported similar rates of stomach-related side effects between probiotic and control groups. However, other safety details were not reported, so it's important to talk to a doctor before giving probiotics to a child.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
ObjectiveThis study aimed to evaluate the comparative efficacy and safety of various probiotic regimens for treating Respiratory tract infections (RTIs) in otherwise healthy children.MethodsSix Chinese and English databases were searched for randomized controlled trials of probiotics for the RTIs in children published from inception to November 15th, 2025. Pairwise meta-analysis and network meta-analysis were used to assess the efficacy and safety.ResultsEight RCTs enrolling 1,158 children aged 0.69 to 6.4 years from Ukraine, China, Malaysia, India, and Italy were included. Bifidobacterium significantly shortened duration of cough, Lactobacillus reduced duration of illness, Lactobacillus+Bifidobacterium reduced both duration of cough and antibiotic use, and the four-strain combination (Lactobacillus+Bifidobacterium+Enterococcus+Bacillus) reduced durations of fever and cough. Low-certainty evidence suggested superior efficacy of the Lactobacillus+Bifidobacterium over both Bifidobacterium and the four-strain combination for reducing duration of cough, and over Lactobacillus for shortening antibiotic use. Stratified analyses revealed strain-specific effects across RTI subtypes: Bifidobacterium shortened cough in LRTI [−1.12 days, (−1.82, −0.42)]; Lactobacillus reduced illness duration in both URTI [−1.31 days, (−2.19, −0.43)] and LRTI [−1.36 days, (−2.29, −0.43)], and shortened antibiotic use in URTI [−1.70 days, (−2.40, −1.00)]; Lactobacillus+Bifidobacterium shortened fever in URTI [−2.00 days, (−2.57, −1.43)], cough in LRTI [−1.25 days, (−1.84, −0.66)], and both fever −7.10 days, (−8.54, −5.66)] and antibiotic use [−10.50 days, (−13.22, −7.78)] in RRTI; the four-strain combination reduced fever [−1.54 days, (−2.40, −0.68)] and cough [−2.51 days, (−3.89, −1.13)] in RRTI. One RCT reported comparable incidence of gastrointestinal adverse events between probiotic and control groups.ConclusionModerate- to high-certainty evidence supports Bifidobacterium for reducing cough duration and Lactobacillus for shortening illness duration in children with RTIs. While Lactobacillus+Bifidobacterium demonstrated large-magnitude reductions in cough duration and antibiotic use, these findings derive from low- to moderate-certainty evidence and require verification through rigorously designed randomized clinical trials. Strain-specific effects varied across RTI subtypes, suggesting the need for tailored probiotic selection. Future research should prioritize validating multi-strain efficacy, establish optimal dosing protocols, and evaluate long-term safety profiles to enable evidence-based guideline development.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251074234, identifier CRD420251074234.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.